Composition :
Clovika 400 is a pink colored film coated caplet containing 400 mg
of acyclovir.
Indications :
Clovika is indicated for the management of Herpes simplex virus infections of the skin and mucous membranes including initial and recurrent Herpes genitalis. For the suppression of recurrent Herpes simplex infections in immunocompetent patients. For the prophylaxis of Herpes simplex infections in immunocompromised individuals.
For the treatment of infections Herpes zoster, varicella (chicken-pox).
Dosage :
Treatment dose of Herpes simpelx in adult.
For the treatment of Herpes simplex infections Clovika 200 should be given 5 times daily with an interval of approximately 4 hours with no administration at night time. The dose should be given for 5 consecutive days, but for severe initials infections the duration of administration may be extended.
For severe immunocompromissed patients (e.g after bone morrow transplantation) or for patients with impaired gastrointestinal absorption, the dosage my be increased to 400 mg. Clovika should be given as soon as possible after infection occurs, for recurrent episodes after the detection of early symptomps os after the appearance of the first lesion.
Adverse reactions :
Rashes have reported occasionally in patients taking acyclovir caplets, they dissapeared after the medications was discontinued Disturbances of digestive track, such as nausea, vomiting, diarrhea and abdominal pain have been reported in several patients treated with acyclovir. In double blind placebo-controlled studies there was no significant difference in the number of gastrointestinal disturbances cases reported between patients taking placebo and those tacking acyclovir. Reversible neurological effect, such as vertigo, mental confusion, hallucination and somnolence have been reported occasionally in patients with renal impairment or other presdiposing factors. Accelarated hair loss have also been reported occasionally. The type of hair loss in related with a variety of processer of the disease and medication. The correlation between hair loss and acyclovir administration has not been established. Other reported cases seldom occur in patients treated orally with acyclovir. These include light transient elevated levels of bilirubin and hepatic enzyme, slight increase in blood urea and creatinine levels, slight lowering of hematological index, headache and fatique
Presentation :
Clovika 400, boxes of 14 blisters of caplet
Reg. No. DKL 9509310317B1 |
